NasdaqGS - Nasdaq Real Time Price USD

XBiotech Inc. (XBIT)

Compare

3.8800

-0.1300

(-3.24%)

At close: January 10 at 4:00:00 PM EST

3.8800

0.00

(0.00%)

After hours: January 10 at 4:20:00 PM EST

XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%

Key Insights Significant control over XBiotech by individual investors implies that the general public has more power...

Simply Wall St. yesterday

XBIT
-3.24%
XBiotech Pauses Rheumatology program

Findings from recently completed Rheumatoid Arthritis Study raise questionsAUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal

GlobeNewswire 19 days ago

XBIT
-3.24%
XBiotech: Q2 Earnings Snapshot

AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Monday reported a loss of $13 million in its second quarter. The Austin, Texas-based company said it had a loss of 43 cents per share.

Associated Press Finance 4 months ago

XBIT
-3.24%
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen

GlobeNewswire 6 months ago

XBIT
-3.24%
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders

Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 10 months ago

XBIT
-3.24%

Performance Overview

Return	XBIT	S&P 500
YTD	-5.13%	-1.35%
1-Year	-14.73%	+22.51%
3-Year	-65.72%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

XBiotech Inc. (XBIT)

XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%

XBiotech Pauses Rheumatology program

XBiotech: Q2 Earnings Snapshot

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders

Performance Overview